OXBRIDGE SENSORS LIMITED

Executive Summary

OXBRIDGE SENSORS LIMITED is a newly incorporated micro-entity with no recorded financial activity or assets to date, resulting in a high risk rating primarily due to lack of operational and financial substance. While regulatory compliance is satisfactory and the biotech research focus is promising, the absence of trading history and sole control by one individual warrant careful scrutiny of future business plans and funding strategies before investment. Further due diligence on operational readiness and governance is recommended.

OXBRIDGE SENSORS LIMITED - Analysis Report

Company Number: 15218575

Analysis Date: 2025-07-20 13:50 UTC

1. Risk Rating: HIGH
   Given the company’s very recent incorporation (October 2023), absence of any financial activity or assets, and zero reported net assets or working capital as of the last accounts date, there is a high risk from a solvency and liquidity perspective. The company currently shows no operational scale or financial substance to meet obligations or support ongoing business operations.

2. Key Concerns:

• Zero Financial Activity and Assets: The micro-entity accounts report no fixed or current assets, no liabilities, and no net assets, indicating no trading or capital investment to date.
• No Employees or Operational Data: The company reports zero employees and no revenue or expenditure, raising questions about operational viability or business commencement.
• Single Shareholder and Director Control: Dr. Nan Wang holds 75-100% of shares and voting rights and is the sole director, concentrating control and potentially limiting corporate governance oversight.

3. Positive Indicators:

• Compliance with Filing Requirements: Accounts and confirmation statements are filed on time with no overdue filings, reflecting good regulatory compliance so far.
• Clear Ownership and Management: Transparent identification of significant control and director details supports accountability.
• Biotechnology R&D Focus: The SIC code indicates a research and experimental development activity in biotechnology, a sector with potential for growth and investment interest.

4. Due Diligence Notes:

• Investigate the company’s business plan and timeline for commencing operations to assess future capital needs and revenue projections.
• Verify any off-balance sheet commitments or external funding arrangements not reflected in the micro-entity accounts.
• Assess the background and capability of the sole director/owner to execute the proposed business activities, including any external advisors or partners.
• Confirm no related party transactions or financial support agreements exist that could impact liabilities or funding structure.